Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1385&sort=title
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=title", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1442&sort=title", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1386&sort=title", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1384&sort=title" }, "data": [ { "type": "Grant", "id": "10490", "attributes": { "award_id": "3U45ES006180-31S1", "title": "UAW Hazardous Material Worker Health and Safety Training (U45)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Environmental Health Sciences (NIEHS)" ], "program_reference_codes": [], "program_officials": [ { "id": 21583, "first_name": "Demia", "last_name": "Wright", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-06-08", "end_date": "2023-05-31", "award_amount": 99180, "principal_investigator": { "id": 23286, "first_name": "ANDY", "last_name": "COMAI", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1584, "ror": "", "name": "INTERNATIONAL UNION, UAW OF AMER AFL-CIO", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23287, "first_name": "Darius D", "last_name": "Sivin", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1584, "ror": "", "name": "INTERNATIONAL UNION, UAW OF AMER AFL-CIO", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true }, "abstract": "The UAW proposes to work with local organizations in high COVID-19 impacted communities to provide culturally and linguistically appropriate education about COVID-19 health risks and protective measures. We will connect community members to needed public health resources such as COVID-19 testing, contact tracing, infection control, medical care and mental health services. The UAW will leverage its relationships with employers in government, community service organizations, manufacturing and gaming to help communities connect to resources such as testing, contact tracing, and effective infection control measures. The UAW and our partners have already developed COVID-19 curricula that use adult learning methods and popular education techniques. These curricula have integrated and expanded upon NIEHS COVID-19 resources and curricula. They are taught in Spanish as well as English and they have been integrated into English as a second language curricula. Over the course of the last two years these materials have been updated to reflect guidance from the CDC, NIOSH, NIH and other federal agencies. These materials can and will be adapted to account for state and local policies and regulations in the two Michigan counties, New York City and Puerto Rico that are relevant to the target training populations. The overall goal of this project is to move communities in Wayne and Oakland counties in Michigan, Puerto Rico and New York City, NY towards a recovery phase in the pandemic in which appropriate public health practices are more widely spread. The specific aims include: 1. Provide community members with culturally and linguistically appropriate education about COVID-19 health risks and protective infection control measures through the delivery of training classes, in-person or online, as appropriate. 2. Connect community members to needed public health resources such as COVID-19 testing, contact tracing, medical care, and mental health services through information provided in training and in informational fact sheets. 3. Using the ongoing pandemic as a model, the UAW will train our community partners in disaster preparedness, response and recovery and transfer knowledge of local disaster preparedness, response, and recovery resources. U-M will refine existing evaluation methods and instruments developed under the parent grant. This will require a Spanish-fluent evaluator trained in public health. Quality assurance will include observation of training and written surveys. Feedback from findings will be provided to trainers. Impact evaluation will assess whether participants were able to access high quality PPE and whether they knew whom to contact for additional information, access to COVID tests, vaccines, boosters, mental health counseling and other community resources.", "keywords": [ "Adult", "COVID test", "COVID-19", "COVID-19 impact", "COVID-19 test", "COVID-19 testing", "Caring", "Centers for Disease Control and Prevention (U.S.)", "Communities", "Community Services", "Contact Tracing", "County", "Disasters", "Education", "Educational Curriculum", "Evaluation", "Feedback", "Goals", "Government", "Hazardous Substances", "Health", "Health Resources", "Impact evaluation", "Infection Control", "Knowledge", "Language", "Linguistics", "Measures", "Medical", "Mental Health Services", "Methods", "Michigan", "Modeling", "National Institute of Environmental Health Sciences", "New York City", "Participant", "Persons", "Phase", "Policies", "Population", "Public Health", "Public Health Practice", "Puerto Rico", "Readiness", "Recovery", "Regulation", "Resources", "Risk", "Safety", "Surveys", "Techniques", "Testing", "Training", "United States National Institutes of Health", "Update", "Vaccines", "Work", "instrument", "learning strategy", "member", "mental health counseling", "pandemic disease", "parent grant", "quality assurance", "response", "service organization" ], "approved": true } }, { "type": "Grant", "id": "7485", "attributes": { "award_id": "3U45ES006180-28S1", "title": "UAW NIEHS Worker Training Program Coronavirus and Infectious Disease Response Training (Admin Supp Clinical Trial Not Allowed)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Environmental Health Sciences (NIEHS)" ], "program_reference_codes": [], "program_officials": [ { "id": 21583, "first_name": "Demia", "last_name": "Wright", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-05-04", "end_date": "2022-05-31", "award_amount": 199584, "principal_investigator": { "id": 23286, "first_name": "ANDY", "last_name": "COMAI", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1584, "ror": "", "name": "INTERNATIONAL UNION, UAW OF AMER AFL-CIO", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23287, "first_name": "Darius D", "last_name": "Sivin", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1584, "ror": "", "name": "INTERNATIONAL UNION, UAW OF AMER AFL-CIO", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true }, "abstract": "The International Union, UAW and its partners propose to conduct training to prevent and reduce exposure to SARS-CoV-2 among healthcare workers, emergency first responders, manufacturing workers, and members of underserved Hispanic/Latino communities. The paramount goal of this project is to provide workers and members of underserved populations identified above with the knowledge, information and skills that they need to protect themselves from Covid-19 and to work with employers and community institutions to establish and implement programs that will protect them from Covid-19. The specific aims of this proposal are: To modify the NIEHS training tool Protecting Yourself from Covid-19 In the Workplace, using material from previously developed UAW curricula on infectious diseases and make it available online. To conduct remote train-the-trainers (TTT) that will train UAW staff and worker-trainers to deliver Covid-19 training and will train them in the use of online platforms for training. To have staff and worker-trainers conduct industry-specific awareness level TTTs for workplace health and safety representatives, health and safety committees and other local union leaders responsible for workplace health and safety. To assist local unions and UAW-represented workplaces and UAW consortium partners to identify hardware and software needs for conducting remote training and to develop realistic plans to meet those needs given available resources. To conduct a remote train-the-trainer (TTT) that will train consortium partners to deliver Covid-19 training. To add a Covid-19 unit to our 40-hour Industrial Emergency Response (IER) technician training, modify the training for delivery online, and deliver one online 40-hour IER class. To modify the NIEHS resiliency training for delivery online and deliver it to UAW members, staff, worker-trainers and UAW health and safety reps to help deal with the emotional strain caused by the pandemic and by responding to it. To conduct program evaluation of all of the above, making use of worker-evaluators, where possible, to provide feedback for continual improvement of curricula and delivery methods.", "keywords": [ "2019-nCoV", "Awareness", "COVID-19", "Charities", "Clinical Trials", "Communicable Diseases", "Communities", "Computer software", "Contracts", "Disease", "Educational Curriculum", "Emergency Situation", "Emergency response", "Emotional", "Exposure to", "Feedback", "Friends", "Fright", "Funding", "Goals", "Health", "Health Personnel", "Hispanics", "Hour", "Industrialization", "Industry", "Institution", "International", "Knowledge", "Latino", "Methods", "Michigan", "Monitor", "National Institute of Environmental Health Sciences", "Outcome", "Perception", "Program Evaluation", "Puerto Rico", "Qualitative Evaluations", "Quantitative Evaluations", "Resources", "Safety", "Stress", "Target Populations", "Trainers Training", "Training", "Training Programs", "Underserved Population", "Universities", "Work", "Workplace", "coronavirus disease", "first responder", "innovation", "member", "outreach services", "pandemic disease", "prevent", "programs", "resilience", "response", "skills", "tool", "web site" ], "approved": true } }, { "type": "Grant", "id": "7791", "attributes": { "award_id": "3R01HL142111-03S1", "title": "Ubiquitin Regulation of K Channels in Health and Disease", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 23604, "first_name": "Ravi C.", "last_name": "Balijepalli", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2018-04-01", "end_date": "2022-02-28", "award_amount": 337499, "principal_investigator": { "id": 23605, "first_name": "Henry M", "last_name": "Colecraft", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 781, "ror": "", "name": "COLUMBIA UNIVERSITY HEALTH SCIENCES", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 781, "ror": "", "name": "COLUMBIA UNIVERSITY HEALTH SCIENCES", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "This proposal is for a COVID-19-related Administrative Supplement for RO1HL142111, “Ubiquitin regulation of K Channels in Health and Disease”. We propose to adapt/apply tools and approaches including, nanobody development and optical assays of membrane proteins, that we have developed for studies in the parent proposal to develop novel solutions for COVID-19. There is an ongoing global pandemic in which a novel Coronavirus, SARS-CoV-2, causes Coronavirus Disease-2019 (COVID-19) that is lethal to a subset of the infected population. To date, there are >1.5 million confirmed COVID-19 cases worldwide with >70,000 fatalities. In the United States, best case scenario projections indicate 100,000 – 240,000 lives will be lost to COVID-19, with a worst case scenario of >2 million deaths. The current pandemic follows two other regional outbreaks of coronaviruses responsible for severe acute respiratory syndrome (SARS-CoV) in 2002, and Middle Eastern respiratory syndrome (MERS-CoV) in 2012, that caused epidemics with fatality rates of 10% and 36%, respectively. All three coronaviruses represent examples of animal to human transmission of infection. Given a high zoonotic reservoir of novel coronaviruses and persistence of close animal/human contact in various parts of the world, the chances of future viral epidemics/pandemics beyond the current crisis is high. Hence, fatal diseases caused by viral infections represent current and future widespread public health challenges, highlighting an urgent need for general strategies that can combat not only COVID-19 but also other future viral outbreaks. SARS-CoV-2 is an enveloped virus that gains access to host cells by using a receptor binding domain (RBD) on a viral surface spike protein (S) to bind to membrane-bound angiotensin-converting enzyme 2 (ACE2) receptors on target cells. Preventing the SARS-CoV-2 S protein/ACE2 receptor interaction is the main principle behind the beneficial effects of neutralizing antibodies in recovered patients, and the scientific premise for an ongoing clinical trial for administration of soluble ACE2 ectodomain. There are ongoing efforts to develop neutralizing monoclonal antibodies (mAb) against SARS-CoV-2 S protein that disrupt interaction with ACE2. While potentially effective, limitations of this approach include high cost, time-consuming, incompatibility with inhalation formulations, and potential for viral mutations that result in escape from mAb-mediated neutralization. This proposal is based on the hypothesis that engineered single-domain antibodies (nanobodies) with high avidity for SARS-CoV-2 S protein can be generated to overcome some of the limitations of neutralizing mAbs and provide potential therapeutic leads for COVID-19. We propose three aims: 1) Isolate and characterize neutralizing and non- neutralizing nanobodies against SARS-CoV-2 S protein; 2) Develop cell-based high throughput fluorescence assay to probe SARS-CoV-2 S protein/ACE2 interaction and internalization; 3) Comparatively evaluate the capacity of engineered nanobodies to disrupt SARS-CoV-2 S protein/ACE2 interaction and internalization", "keywords": [ "2019-nCoV", "Administrative Supplement", "Affinity", "Animals", "Avidity", "Binding", "Biological Assay", "COVID-19", "COVID-19 pandemic", "Camels", "Cells", "Cellular Assay", "Cessation of life", "Chimeric Proteins", "Chiroptera", "Clinical Trials", "Consumption", "Coronavirus", "Data", "Development", "Disease", "Disease Outbreaks", "Endocytosis", "Engineering", "Epidemic", "Fatality rate", "Fluorescence", "Formulation", "Future", "Health", "Human", "Infection", "Inhalation", "Lead", "Libraries", "Mediating", "Membrane", "Membrane Proteins", "Middle East Respiratory Syndrome Coronavirus", "Monitor", "Monoclonal Antibodies", "Mutation", "Optics", "Parents", "Pathogenesis", "Patients", "Peptidyl-Dipeptidase A", "Population", "Potassium Channel", "Process", "Production", "Property", "Protein Biochemistry", "Proteins", "Public Health", "Regulation", "Reporting", "Resources", "SARS coronavirus", "Severe Acute Respiratory Syndrome", "Surface", "Syndrome", "Therapeutic", "Time", "Ubiquitin", "United States", "Viral", "Virus Diseases", "Yeasts", "Zoonoses", "base", "combat", "comparative", "cost", "efficacy testing", "inhibitor/antagonist", "nanobodies", "neutralizing antibody", "neutralizing monoclonal antibodies", "novel", "novel coronavirus", "pandemic disease", "prevent", "protein transport", "receptor", "receptor binding", "respiratory", "tool", "transmission process", "virus envelope" ], "approved": true } }, { "type": "Grant", "id": "9177", "attributes": { "award_id": "3U54HL119893-07S1", "title": "UC BRAID Center for Accelerated Innovation COVID-19 diagnostic project development", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [ { "id": 24937, "first_name": "KATHLEEN T", "last_name": "ROUSCHE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-08-06", "end_date": "2022-07-31", "award_amount": 2760000, "principal_investigator": { "id": 24938, "first_name": "MICHAEL J", "last_name": "PALAZZOLO", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 818, "ror": "", "name": "UNIVERSITY OF CALIFORNIA LOS ANGELES", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 818, "ror": "", "name": "UNIVERSITY OF CALIFORNIA LOS ANGELES", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "The University of California Center for Accelerated Innovation created new mechanisms leveraging its diverse strengths in diagnostics, therapeutics, and devices to support translation of promising early-stage inventions for patient benefit. The Center is a consortium of five UC medical campuses: UC Davis, UC Irvine, UC Los Angeles, UC San Diego, and UC San Francisco. Each campus has a thriving research enterprise, nationally ranked medical school, and translational research institute funded by Clinical and Translational Science Awards (CTSA). The Center taps into the vigor and creativity of California's legendary biomedical and engineering ecosystem and integrates the many successful business, engineering and health sciences programs at our campuses. Our program partners with well-established biomedical companies, venture capital firms, industry organizations and nonprofits focused on medical innovation. The Center is supported by UC Biomedical Research Acceleration, Integration, and Development (UC BRAID), a joint effort of the five UC biomedical campuses designed to catalyze and accelerate biomedical, clinical, and translational research across the UC system. Together we: 1) Engage University of California heart, lung and blood disease innovators in entrepreneurism through a comprehensive education, training and mentorship program. 2) Solicit and select technologies with high commercial potential that align with NHLBI's mission and addressed unmet medical needs or significant scientific opportunity. 3) Incubate our most promising technologies in accordance with industry requirements to facilitate their translation to commercial products that improve patient care and enhance health. We are now leveraging this infrastructure and our network to support the development of COVID-19 diagnostic technologies of high priority to the NIH.", "keywords": [ "Acceleration", "Address", "Biomedical Engineering", "Biomedical Research", "Businesses", "COVID-19", "California", "Capital", "Clinical Research", "Clinical and Translational Science Awards", "Creativeness", "Development", "Devices", "Diagnostic", "Diagnostic tests", "Ecosystem", "Engineering", "Faculty", "Funding", "Health", "Health Sciences", "Heart Diseases", "Hematological Disease", "Incubated", "Industry", "Infrastructure", "Joints", "Los Angeles", "Lung diseases", "Medical", "Medical Device", "Mentorship", "Mission", "National Heart Lung and Blood Institute", "Patient Care", "Patients", "Pharmaceutical Preparations", "Research", "Research Institute", "San Francisco", "System", "Technology", "Therapeutic", "Training and Education", "Translational Research", "Translations", "United States National Institutes of Health", "Universities", "design", "improved", "innovation", "invention", "medical schools", "programs" ], "approved": true } }, { "type": "Grant", "id": "2506", "attributes": { "award_id": "2011924", "title": "UC San Diego MRSEC: an NSF Materials Research Science and Engineering Center", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Mathematical and Physical Sciences (MPS)", "MATERIALS RSCH SCI & ENG CENT" ], "program_reference_codes": [], "program_officials": [ { "id": 7140, "first_name": "Miriam", "last_name": "Deutsch", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-09-01", "end_date": "2026-08-31", "award_amount": 18000000, "principal_investigator": { "id": 7145, "first_name": "Michael", "last_name": "Sailor", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 258, "ror": "", "name": "University of California-San Diego", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 7141, "first_name": "Ying S", "last_name": "Meng", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 7142, "first_name": "Andrea R", "last_name": "Tao", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 7143, "first_name": "Nicole F", "last_name": "Steinmetz", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 7144, "first_name": "Jonathan K", "last_name": "Pokorski", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 258, "ror": "", "name": "University of California-San Diego", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Nontechnical Abstract: The growth, prosperity, security, and quality of life of humans are in large part determined by the materials they use. The mission of the UC San Diego Materials Research Science and Engineering Center (UCSD MRSEC) is to perform innovative, interdisciplinary materials research relevant to societal needs, and to prepare students to become future leaders in materials design and discovery. The research effort of the Center is conducted within two highly interdisciplinary groups. The first group is deploying the most powerful computers available to understand, predict, and ultimately control the properties of materials at microscopic size scales—sizes just larger than molecular dimensions. It is in this size regime where many useful properties of materials emerge. For example, changes in the shape of metal particles at this scale can change their color, their efficiency as a catalyst, or their sensitivity in a medical diagnostic test. The second group is using the tools of the biotechnology revolution—in particular, genetic engineering and synthetic biology—to build new classes of materials that can respond to stimuli from their environment in useful ways. Both groups are targeting fundamental breakthroughs that can impact a number of critically important needs: faster, more accurate sensors for medical diagnostic tests, more efficient decontamination of chemical or biological hazards, better catalysts to reduce the cost of industrial processes, and improved therapeutics for treating diseases. The fundamental research within the two groups is empowered by an integrated educational program to prepare a diverse community of trainees to enhance national proficiencies in the science, technology, engineering, and mathematics fields. Immersive training for scientists across all levels – novice through established – develops technical competency in laboratory procedures, advanced instrumentation, and computational methods. Internship and scientist-in-residence programs fuel vital exchange of ideas and leverage partnerships with industry, national laboratories, and other collaborators. Partnership with the Fleet Science Center builds researchers’ skills in science communication and connects the UCSD MRSEC with the diverse San Diego community to address community-articulated needs. \n\nTechnical Abstract: The UCSD MRSEC addresses two fundamental challenges: (1) How to predict and direct the assembly of materials at the mesoscale, where macroscopic behavior and properties emerge (IRG1: Predictive Assembly); and (2) How to deploy the tools of synthetic biology to build soft materials that meld the characteristics of living systems with the performance requirements of advanced engineered materials (IRG2: Stimuli-Responsive Living Polymeric Materials). IRG1 focuses on the rational design of innovative, functional mesomaterials with programmed plasmonic, catalytic, and structural properties. A computation-driven framework is being created to understand, predict, and design how shaped nanocomponents are used as material building blocks. The models developed bridge length and time scales relevant to mesoscale assembly. IRG2 integrates engineered living matter – photosynthetic organisms – into biological composites that respond to stimuli with genetically encoded outputs, such as chemical reagents and polymer feedstocks. The UCSD MRSEC creates unique resources to benefit the broader materials-research community: a MesoMaterials Design Facility – a virtual, computational facility, and an Engineered Living Materials Foundry, consisting of a bio-synthesis laboratory and soft-matter characterization tools. The Center’s educational goals include preparing the next generation of interdisciplinary materials scientists, and increasing diversity and inclusion in materials research. The Research Immersion in Materials Science and Engineering (RIMSE) Summer Schools provide intensive training in the areas of IRG research. Enabling professional development for Center members in science communication, a partnership with the Fleet Science Center facilitates meaningful engagement with the diverse San Diego community.\n\nThis award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "7328", "attributes": { "award_id": "3P20CA233307-02S1", "title": "UChicago Interdisciplinary Cancer Health Disparities SPORE", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [ { "id": 23115, "first_name": "Tiffany A", "last_name": "Wallace", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2018-09-01", "end_date": "2021-08-31", "award_amount": 162000, "principal_investigator": { "id": 23116, "first_name": "Dezheng", "last_name": "Huo", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 289, "ror": "https://ror.org/024mw5h28", "name": "University of Chicago", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23117, "first_name": "Rita", "last_name": "Nanda", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 23118, "first_name": "OLUFUNMILAYO F.", "last_name": "OLOPADE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 289, "ror": "https://ror.org/024mw5h28", "name": "University of Chicago", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true }, "abstract": "This application is being submitted in response to the Notice of Special Interest (NOSI) identified as NOTCA-20-042. The ongoing pandemic of the coronavirus disease 2019 (COVID-19) is a public health and economic emergency that has disrupted the lives of breast cancer patients. Unfortunately, it has hit the United States heavily with more than 1.7 million people having been infected and more than 100,000 lives lost to date. While old age and having comorbidities are risk factors for dying from COVID-19, there is also a racial disparity in COVID-19 severity, with black and Latino patients in urban centers dying disproportionately from COVID-19. Breast cancer is the most common malignancy in women, with over 3.8 million women living in the United States with a history of invasive breast cancer. African Americans with breast cancer have an elevated risk of all-cause mortality and breast cancer-specific mortality. During the COVID-19 pandemic, it is important to understand the impact of SARS-CoV-2 infection and COVID-19 on breast cancer disease progression, care delivery, and survivorship including quality of life during and after the COVID-19 outbreak. In response to the needs of patients participating in our P20 funded UChicago Interdisciplinary Health Disparities SPORE and to address these knowledge gaps, we propose to engage with the Community by conducting an online survey, reviewing electronic health records, and searching the National Death Index to determine status of 3,059 breast cancer patients in the Chicago Multiethnic Epidemiologic Breast Cancer Cohort. The project has three specific aims: First, we will evaluate the extent of treatment interruption because of COVID-19 outbreak, and understand the utilization and satisfaction with Telehealth. Second, we will conduct a holistic evaluation of COVID-19 and mitigation efforts on loneliness, anxiety, stress, economic impact, and lack of resources among breast cancer patients. Third, we will estimate the coronavirus infection rate, severity and case-fatality rate of COVID-19, and identify factors associated with severity and case-fatality rate of COVID-19. For each aim, we will examine racial differences to understand whether COVID-19 has worsened previously identified mortality gap in the Cohort. The Supplementary Project will greatly enhance our SPORE P20 program by supporting additional interviews and follow-up of the cancer cohort members, and will generate necessary data regarding the impact of COVID-19 epidemic and lockdown on translational research to close the mortality gap in our proposed full SPORE application. These data are critical for guiding both community level interventions and health systems adaptation to support high-risk patients in the era of COVID-19.", "keywords": [ "2019-nCoV", "Address", "Admission activity", "Affect", "African American", "Age", "Anxiety", "Area", "Breast Cancer Patient", "Breast Cancer Treatment", "Breast Cancer survivor", "COVID-19", "COVID-19 pandemic", "Cancer Patient", "Cancer Survivor", "Case Fatality Rates", "Catchment Area", "Caucasians", "Cessation of life", "Chicago", "Chronic lung disease", "Code", "Communities", "Coronavirus", "Coronavirus Infections", "County", "Data", "Diabetes Mellitus", "Disease", "Disease Outbreaks", "Disease Progression", "Elderly", "Electronic Health Record", "Emergency Situation", "Enrollment", "Epidemiology", "Evaluation", "Exposure to", "Funding", "Grant", "Health system", "Healthcare", "High-Risk Cancer", "Histologic", "Hypertension", "Illinois", "Incidence", "Infection", "Interruption", "Intervention", "Interview", "Knowledge", "Latino", "Loneliness", "Malignant Neoplasms", "Outcome", "Patients", "Persons", "Phenotype", "Population", "Psychological Impact", "Public Health", "Quality of life", "Race", "Recording of previous events", "Resources", "Risk", "Risk Factors", "Severities", "Severity of illness", "Side", "Social isolation", "Social support", "Stress", "Surveys", "Telemedicine", "Translational Research", "United States", "Universities", "Woman", "aged", "cancer health disparity", "cancer therapy", "care delivery", "cohort", "comorbidity", "cooking", "economic impact", "ethnic minority population", "follow-up", "health disparity", "health economics", "high risk", "indexing", "infection rate", "interest", "malignant breast neoplasm", "member", "metropolitan", "mortality", "news", "novel coronavirus", "pandemic disease", "programs", "racial and ethnic", "racial difference", "racial disparity", "racial health disparity", "response", "satisfaction", "screening guidelines", "survivorship", "telehealth", "ventilation" ], "approved": true } }, { "type": "Grant", "id": "7811", "attributes": { "award_id": "3UM1AI069424-14S1", "title": "UCLA AIDS Prevention and Treatment Clinical Trials Unit", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 23622, "first_name": "Jessica R.", "last_name": "Landis", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-06-03", "end_date": "2020-11-30", "award_amount": 300001, "principal_investigator": { "id": 21581, "first_name": "Judith S.", "last_name": "Currier", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 818, "ror": "", "name": "UNIVERSITY OF CALIFORNIA LOS ANGELES", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 818, "ror": "", "name": "UNIVERSITY OF CALIFORNIA LOS ANGELES", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "A novel pneumonia caused by a previously unknown betacoronavirus emerged in Wuhan, China, in December 2019. The virus is closely related to the severe acute respiratory syndrome coronavirus (SARS CoV-1), which led to an outbreak in 2003, and has been named SARS-CoV-2. The human disease caused by SARS-CoV-2 is called COVID-19. During the current SARS-CoV-2 outbreak, the incidence of known cases has rapidly increased such that, on January 5, 2020, there were 59 confirmed cases, 278 cases on January 20, 2118 cases on January 26, and more than 80,000 cases and 2700 deaths as of February 25, 2020, according to various international health reporting agencies. As a result, on January 30, 2020, the International Health Regulations Emergency Committee of the World Health Organization (WHO) declared the COVID-19 outbreak a Public Health Emergency of International Concern. On January 31, 2020, the US Department of Health and Human Services declared a public health emergency in the United States. As of March 21, 2020, there are 297,090 cases of COVID-19, including 22,177 cases in the United States (US), resulting in a total of 12,755 deaths globally. Despite quarantine measures, SARS-CoV-2 continues to spread (1). Outbreak forecasting and modeling suggest that these numbers will continue to rise (2). At present, there is no specific antiviral therapy for COVID-19. Few treatment studies have been conducted because most human CoV strains cause self-limited disease, and care is supportive. After SARS-CoV-1 was identified in 2002-2003 and caused a large global outbreak, there was an increased interest in the development of specific therapeutic agents. SARS-CoV-1 patients were treated with corticosteroids, type 1 IFN agents, convalescent plasma, ribavirin, and lopinavir or ritonavir; except for ribavirin, many of these agents have in vitro pre-clinical data that support their efficacy (3-11). Since the SARS-CoV-1 outbreak in 2002-2003, new therapeutic agents targeting viral entry proteins, proteases, polymerases, and methyltransferases have been tested; however, none of them has been shown to be efficacious in clinical trials (12-19). Recent press-release and non-peer reviewed information suggests potential efficacy for a subset of SARS-CoV-2 patients, but this remains to be reviewed and presented in peer-reviewed formats with sufficient granularity to be clinically impactful. Given the continued spread of and lack of specific antiviral therapy for SARS-CoV-2 infection, this project will support additional testing and research to identify persons with SARS-CoV-2, and support infrastructure to increase testing and conduct research on SARS-CoV-2 therapeutics and prevention in a safe and innovative environment.", "keywords": [ "2019-nCoV", "Acquired Immunodeficiency Syndrome", "Adrenal Cortex Hormones", "Antiviral Therapy", "Area", "COVID-19", "Caring", "Cessation of life", "China", "Clinical", "Clinical Data", "Clinical Treatment", "Clinical Trials", "Clinical Trials Unit", "Development", "Disease", "Disease Outbreaks", "Domiciles", "Emergency Situation", "Environment", "Guidelines", "Health", "Homelessness", "Immunocompromised Host", "In Vitro", "Incidence", "Individual", "Infection", "Infrastructure", "Interferons", "International", "Link", "Lopinavir", "Los Angeles", "Measures", "Methyltransferase", "Modeling", "Names", "Nose", "Patients", "Peer Review", "Peptide Hydrolases", "Persons", "Plasma", "Pneumonia", "Polymerase", "Population", "Press Releases", "Prevention", "Proteins", "Quarantine", "Regulation", "Reporting", "Research", "Resources", "Ribavirin", "Ritonavir", "SARS coronavirus", "Self Administration", "Swab", "Testing", "Therapeutic", "Therapeutic Agents", "United States", "United States Dept. of Health and Human Services", "Viral", "Virus", "World Health Organization", "housing instability", "human coronavirus", "human disease", "innovation", "interest", "novel", "novel therapeutics", "pre-clinical", "public health emergency", "standard of care", "targeted treatment" ], "approved": true } }, { "type": "Grant", "id": "6470", "attributes": { "award_id": "3U19AI077439-13S2", "title": "UCSF COVID-19 Immunophenotyping Clinical Study and Core Laboratories", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 21721, "first_name": "Gang", "last_name": "Dong", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-05-08", "end_date": "2022-03-31", "award_amount": 5742559, "principal_investigator": { "id": 21722, "first_name": "David J", "last_name": "Erle", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 768, "ror": "https://ror.org/043mz5j54", "name": "University of California, San Francisco", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "COVID-19, the pandemic illness caused by the novel virus SARS-CoV-2, is a serious respiratory illness that has high infectivity and a mortality rate that varies from <1% to up to 20% depending on underlying risk factors. Indeed, disease severity varies markedly based on recognized clinical risk factors (age and co-morbidities). The biological underpinnings of this clinical variability are unknown but likely relate to variation in both the virus and the host response. A detailed understanding of the risk factors for severe disease, including genetic and environmental factors and the nature of the host immunological response, is essential for the development of prognostic biomarkers and effective therapies. To meet this urgent need we propose to help develop and to participate in the IMPACC multi-center longitudinal clinical study of hospitalized patients with COVID-19 and to immunophenotype participants using shared immunological methods that will be designed an carried out by core laboratories at UCSF and at other participating institutions. Our specific aims are 1) to develop a prospective observational convenience cohort of adult subjects hospitalized with known or presumptive COVID-19, 2) to use this cohort to describe the relationship between specific immunologic assessments and clinical course of COVID-19 in hospitalized patients, and 3) to implement three core laboratories at UCSF to support immunophenotyping in this multicenter cohort. These core laboratories will perform bulk RNA sequencing of blood peripheral blood mononuclear cells (PBMC), bulk metagenomic next-generation sequencing (mNGS) on endotracheal aspirate samples, and serologic phage display assays (PhIP-Seq). Successful completion of these aims will yield critical information regarding the relationship between viral load, host immunological responses, and poor clinical outcomes that are urgently needed for biomarker development and rational therapeutic targeting. In addition, the cellular samples banked in this study may directly contribute to the development of neutralizing antibodies and vaccine strategies that will be our ultimate defense against recurrence of this extraordinary pandemic. A rapid and robust scientific and medical response of the type proposed by the NIAID and the academic community in this consortium is an essential element of a broad response required to protect the health and well-being of all individuals, our health care system, and the broader social structures that maintain global health and welfare.", "keywords": [ "2019-nCoV", "Adult", "Affect", "Age", "Aspirate substance", "Biological", "Biological Assay", "COVID-19", "COVID-19 pandemic", "Case Fatality Rates", "China", "Chronic", "Clinical", "Clinical Research", "Clinical Trials", "Communities", "Coronavirus", "DNA Sequencing Facility", "Development", "Diabetes Mellitus", "Disease", "Disease Outcome", "Elements", "Enrollment", "Environmental Risk Factor", "Family", "General Hospitals", "Genetic", "Genetic Risk", "Health", "Healthcare Systems", "Hypertension", "Immune System Diseases", "Immune response", "Immunologics", "Immunophenotyping", "Individual", "Infection", "Institution", "Intervention", "Investigation", "Laboratories", "Lung diseases", "Medical", "Medical center", "Metagenomics", "Methods", "Myocardial Ischemia", "National Institute of Allergy and Infectious Disease", "Nature", "Onset of illness", "Outcome", "Participant", "Pathogenicity", "Patients", "Peripheral Blood Mononuclear Cell", "Personal Satisfaction", "Phage Display", "Phage ImmunoPrecipitation Sequencing", "Pharmaceutical Preparations", "Pneumonia", "Prognostic Marker", "Recurrence", "Resources", "Risk Factors", "Sample Size", "Sampling", "San Francisco", "Serological", "Serum", "Severity of illness", "Site", "Therapeutic Agents", "Variant", "Viral Load result", "Virus", "base", "biomarker development", "clinical center", "clinical risk", "cohort", "comorbidity", "design", "effective therapy", "endotracheal", "global health", "health care availability", "improved", "inclusion criteria", "member", "mortality", "neutralizing antibody", "neutralizing vaccine", "next generation sequencing", "novel", "novel therapeutics", "novel virus", "pandemic disease", "pathogen", "peripheral blood", "prospective", "respiratory", "response", "social structure", "therapeutic target", "transcriptome sequencing", "trauma centers", "welfare" ], "approved": true } }, { "type": "Grant", "id": "6471", "attributes": { "award_id": "3U19AI077439-13S1", "title": "UCSF COVID-19: Extended Immunophenotyping Studies", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 21723, "first_name": "Gang", "last_name": "Dong", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-05-08", "end_date": "2022-03-31", "award_amount": 1117573, "principal_investigator": { "id": 21724, "first_name": "David J", "last_name": "Erle", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 768, "ror": "https://ror.org/043mz5j54", "name": "University of California, San Francisco", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "We propose to rapidly apply key assays of patient samples derived from IMPACC studies to understand the critical features that characterize hospitalized patients with COVID-19, a pandemic disease characterized by immune exacerbations of lung injury. These proposed studies are a natural and focused extension of the work we are performing in the parent U19 award adapted to the urgent medical need to better understand the pathogenesis of severe, life-threatening COVID-19 disease. We propose 5 site-specific studies that are highly complementary to assays being performed by the IMPACC national immunophenotyping cores here at UCSF and elsewhere. These include studies that focus on both airway cells and blood immune cells (including neutrophils) and utilize a set of innovative methods that allow for a detailed understanding of the nature and activation states of specific cell types within the airway and the blood. These studies promise to yield new insights relevant for understanding COVID-19 immunopathogenesis and predicting disease outcome and response to therapy, and could lead to novel therapeutic targets for this devastating disease.", "keywords": [ "2019-nCoV", "Address", "Adult Respiratory Distress Syndrome", "Adverse effects", "Antibodies", "Aspirate substance", "Asthma", "Award", "Binding", "Biological Assay", "Blood", "COVID-19", "Cell surface", "Cells", "Cessation of life", "Clinical Research", "Cohort Studies", "Complement", "Coronavirus", "Cytometry", "Disease", "Disease Outcome", "Epithelial Cells", "Epitopes", "Evaluation", "Exposure to", "Gene Expression", "Gene Expression Profile", "Genetic Transcription", "Goals", "Human", "Immune", "Immune response", "Immune system", "Immunobiology", "Immunophenotyping", "Individual", "Infection", "Integration Host Factors", "Lead", "Life", "Lung", "Measures", "Mediating", "Medical", "Methods", "Molecular", "Nature", "Outcome", "Parents", "Pathogenesis", "Pathology", "Patients", "Pattern", "Peripheral", "Peripheral Blood Mononuclear Cell", "Pneumonia", "Population", "Proteome", "Recovery", "Recurrence", "Resolution", "Role", "Sampling", "Signal Transduction", "Site", "Standardization", "Testing", "Time", "Transcript", "Tumor-infiltrating immune cells", "Viral", "Work", "cell type", "cohort", "coronavirus disease", "cross reactivity", "cytokine", "cytokine release syndrome", "extracellular", "immune activation", "immunopathology", "innovation", "insight", "longitudinal analysis", "lung injury", "mortality", "neutrophil", "new therapeutic target", "novel", "pandemic disease", "response", "sample fixation", "single-cell RNA sequencing", "transcriptome sequencing", "vaccine candidate" ], "approved": true } }, { "type": "Grant", "id": "9813", "attributes": { "award_id": "1P30AI168440-01", "title": "UCSF-UCB TRAC Clinical Sciences Core", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-08-02", "end_date": "2027-05-31", "award_amount": 207465, "principal_investigator": { "id": 25673, "first_name": "Priya B.", "last_name": "Shete", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 768, "ror": "https://ror.org/043mz5j54", "name": "University of California, San Francisco", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "– Clinical Science Core Progress towards meeting global public health tuberculosis (TB) targets for reductions in incidence, mortality and catastrophic costs have been slow, and appear to have stagnated due the recent COVID-19 pandemic. Without reinvigorating TB clinical research with an infusion of new investigators, novel perspectives, and cutting-edge innovation, we remain at risk of allowing the TB pandemic to continue unabated. The goal of the Clinical Science Core of the UCSF-UCB TRAC is to augment existing UCSF and UCB resources to accelerate clinical research by engaging New Investigators and established investigators new-to-TB, and by reducing the barrier to conducting high-quality, innovating clinical research. UCSF-UCB TRAC Clinical Science Core will support investigators by 1) providing consultation on key aspects of TB clinical research; 2) providing consultation about novel methodologic approaches in clinical research that may be applied to TB; 3) facilitating access to clinical cohorts, datasets, bio-specimens, and clinical research tools; 4) supporting meaningful community engagement via a TRAC TB Community Advisory Board; 5) supporting career development of new investigators with targeted mentorship. The Clinical Science Core will encourage an interdisciplinary approach to TB clinical research by making services and resources available for researchers from diverse fields including basic sciences, epidemiology, bioinformatics, public health, social sciences and clinical sciences. The Clinical Science Core hopes to attract and inspire a new generation of TB scientists to accelerate TB biomedical and clinical research with the support of UCSF-UCB TRAC faculty who are leaders in TB clinical sciences.", "keywords": [ "Affect", "Area", "Basic Science", "Bioinformatics", "Biological", "Biomedical Research", "Biometry", "COVID-19 pandemic", "Caring", "Clinical", "Clinical Research", "Clinical Sciences", "Collaborations", "Communities", "Conceptions", "Consultations", "Data", "Data Science", "Data Set", "Databases", "Development", "Discipline", "Disease", "Dissemination and Implementation", "Doctor of Philosophy", "Ecosystem", "Epidemiology", "Evaluation", "Faculty", "Feedback", "Fostering", "Generations", "Goals", "Health Status", "Human", "Human Subject Research", "Incidence", "Individual", "Infrastructure", "Infusion procedures", "International", "Intervention Trial", "Investigation", "Link", "Mentors", "Mentorship", "Methodology", "Methods", "Outcome", "Participant", "Population Sciences", "Populations at Risk", "Prevention", "Prospective cohort", "Public Health", "Research", "Research Design", "Research Methodology", "Research Personnel", "Resources", "Risk", "Scientist", "Services", "Social Sciences", "Source", "Specimen", "Statistical Data Interpretation", "Training", "Tuberculosis", "base", "bench to bedside", "career development", "clinical center", "clinical research site", "cohort", "community center", "community engagement", "cost", "data management", "design", "experience", "improved", "innovation", "interdisciplinary approach", "meetings", "mortality", "multidisciplinary", "novel", "pandemic disease", "population health", "programs", "repository", "research study", "scale up", "searchable database", "tool", "translational study" ], "approved": true } } ], "meta": { "pagination": { "page": 1385, "pages": 1442, "count": 14420 } } }